<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">26780746</PMID>
      <DateCompleted>
        <Year>2016</Year>
        <Month>10</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>11</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1573-742X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>41</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2016</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of thrombosis and thrombolysis</Title>
          <ISOAbbreviation>J Thromb Thrombolysis</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism.</ArticleTitle>
        <Pagination>
          <StartPage>187</StartPage>
          <EndPage>205</EndPage>
          <MedlinePgn>187-205</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s11239-015-1319-y</ELocationID>
        <Abstract>
          <AbstractText>Venous thromboembolism (VTE) is a serious and often fatal medical condition with an increasing incidence. The treatment of VTE is undergoing tremendous changes with the introduction of the new direct oral anticoagulants and clinicians need to understand new treatment paradigms. This article, initiated by the Anticoagulation Forum, provides clinical guidance based on existing guidelines and consensus expert opinion where guidelines are lacking. Well-managed warfarin therapy remains an important anticoagulant option and it is hoped that anticoagulation providers will find the guidance contained in this article increases their ability to achieve optimal outcomes for their patients with VTE Pivotal practical questions pertaining to this topic were developed by consensus of the authors and were derived from evidence-based consensus statements whenever possible. The medical literature was reviewed and summarized using guidance statements that reflect the consensus opinion(s) of all authors and the endorsement of the Anticoagulation Forum's Board of Directors. In an effort to provide practical and implementable information about VTE and its treatment, guidance statements pertaining to choosing good candidates for warfarin therapy, warfarin initiation, optimizing warfarin control, invasive procedure management, excessive anticoagulation, subtherapeutic anticoagulation, drug interactions, switching between anticoagulants, and care transitions are provided.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Witt</LastName>
            <ForeName>Daniel M</ForeName>
            <Initials>DM</Initials>
            <AffiliationInfo>
              <Affiliation>University of Utah College of Pharmacy, 30 South 2000 East, Salt Lake City, UT, 84112, USA. dan.witt@pharm.utah.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Clark</LastName>
            <ForeName>Nathan P</ForeName>
            <Initials>NP</Initials>
            <AffiliationInfo>
              <Affiliation>Clinical Pharmacy Anticoagulation and Anemia Services, Kaiser Permanente Colorado, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Services, Aurora, CO, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kaatz</LastName>
            <ForeName>Scott</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Hurley Medical Center, Flint, MI, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>College of Human Medicine, Michigan State University, East Lansing, MI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schnurr</LastName>
            <ForeName>Terri</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Thromboembolism Research and Thoracic Surgery Research, St. Joseph's Healthcare, Hamilton, ON, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ansell</LastName>
            <ForeName>Jack E</ForeName>
            <Initials>JE</Initials>
            <AffiliationInfo>
              <Affiliation>Hofstra North Shore/LIJ School of Medicine, Hempstead, NY, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Thromb Thrombolysis</MedlineTA>
        <NlmUniqueID>9502018</NlmUniqueID>
        <ISSNLinking>0929-5305</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>5Q7ZVV76EI</RegistryNumber>
          <NameOfSubstance UI="D014859">Warfarin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017410" MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054556" MajorTopicYN="N">Venous Thromboembolism</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014859" MajorTopicYN="N">Warfarin</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Anticoagulation</Keyword>
        <Keyword MajorTopicYN="N">Anticoagulation clinics</Keyword>
        <Keyword MajorTopicYN="N">Anticoagulation-related bleeding</Keyword>
        <Keyword MajorTopicYN="N">Coumadin</Keyword>
        <Keyword MajorTopicYN="N">Direct oral anticoagulants (DOAC)</Keyword>
        <Keyword MajorTopicYN="N">Drug interactions</Keyword>
        <Keyword MajorTopicYN="N">INR</Keyword>
        <Keyword MajorTopicYN="N">Risk factors</Keyword>
        <Keyword MajorTopicYN="N">Venous thromboembolism</Keyword>
        <Keyword MajorTopicYN="N">Warfarin</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2016</Year>
          <Month>1</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2016</Year>
          <Month>1</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2016</Year>
          <Month>10</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">26780746</ArticleId>
        <ArticleId IdType="pmc">PMC4715850</ArticleId>
        <ArticleId IdType="doi">10.1007/s11239-015-1319-y</ArticleId>
        <ArticleId IdType="pii">10.1007/s11239-015-1319-y</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Ageno W, Gallus AS, Wittkowsky A, et al.  Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College Of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e44S–e88S. doi: 10.1378/chest.11-2292.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1378/chest.11-2292</ArticleId>
            <ArticleId IdType="pmc">PMC3278051</ArticleId>
            <ArticleId IdType="pubmed">22315269</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holbrook A, Schulman S, Witt DM, et al.  Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e152S–e184S. doi: 10.1378/chest.11-2295.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1378/chest.11-2295</ArticleId>
            <ArticleId IdType="pmc">PMC3278055</ArticleId>
            <ArticleId IdType="pubmed">22315259</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palareti G, Legnani C, Cosmi B, Guazzaloca G, Cini M, Mattarozzi S. Poor anticoagulation quality in the first three months after unprovoked venous thromboembolism is a risk factor for long-term recurrence. J Thromb Haemost. 2005;3:955–961. doi: 10.1111/j.1538-7836.2005.01330.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1538-7836.2005.01330.x</ArticleId>
            <ArticleId IdType="pubmed">15869591</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palareti G, Legnani C, Guazzaloca G, et al.  Risk factors for highly unstable response to oral anticoagulation: a case-control study. Br J Haematol. 2005;129:72–78. doi: 10.1111/j.1365-2141.2005.05417.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2141.2005.05417.x</ArticleId>
            <ArticleId IdType="pubmed">15801958</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heit JA, Lahr BD, Petterson TM, Bailey KR, Ashrani AA, Melton LJ., 3rd Heparin and warfarin anticoagulation intensity as predictors of recurrence after deep vein thrombosis or pulmonary embolism: a population-based cohort study. Blood. 2011;118:4992–4999. doi: 10.1182/blood-2011-05-357343.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2011-05-357343</ArticleId>
            <ArticleId IdType="pmc">PMC3208304</ArticleId>
            <ArticleId IdType="pubmed">21890644</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nordstrom BL, Evans MA, Murphy BR, Nutescu EA, Schein JR, Bookhart BK. Risk of recurrent venous thromboembolism among deep vein thrombosis and pulmonary embolism patients treated with warfarin. Curr Med Res Opin. 2014;31(3):439–447. doi: 10.1185/03007995.2014.998814.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1185/03007995.2014.998814</ArticleId>
            <ArticleId IdType="pubmed">25495136</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garcia P, Ruiz W, Loza Munarriz C. Warfarin initiation nomograms for venous thromboembolism. Cochrane Database Syst Rev. 2013;7:CD007699.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23839808</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen SY, Wu N, Gulseth M, et al.  One-year adherence to warfarin treatment for venous thromboembolism in high-risk patients and its association with long-term risk of recurrent events. J Manag Care Pharm. 2013;19:291–301. doi: 10.5428/pcar20130417.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5428/pcar20130417</ArticleId>
            <ArticleId IdType="pubmed">23627575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kearon C, Akl EA, Comerota AJ, et al.  Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: american college of chest physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e419S–e494S. doi: 10.1378/chest.11-2301.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1378/chest.11-2301</ArticleId>
            <ArticleId IdType="pmc">PMC3278049</ArticleId>
            <ArticleId IdType="pubmed">22315268</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Konstantinides SV, Torbicki A, et al.  2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Endorsed by the European Respiratory Society (ERS) Eur Heart J. 2014;35:3033–3069. doi: 10.1093/eurheartj/ehu243.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/eurheartj/ehu243</ArticleId>
            <ArticleId IdType="pubmed">25173341</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Venous Thromboembolic Diseases  . The management of venous thromboembolic diseases and the role of thrombophilia testing. London: National Institute for Health and Clinical Excellence. Clinical Guideline; 2012. </Citation>
        </Reference>
        <Reference>
          <Citation>Wattanakit K, Cushman M. Chronic kidney disease and venous thromboembolism: epidemiology and mechanisms. Curr Opin Pulm Med. 2009;15:408–412. doi: 10.1097/MCP.0b013e32832ee371.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MCP.0b013e32832ee371</ArticleId>
            <ArticleId IdType="pmc">PMC2811494</ArticleId>
            <ArticleId IdType="pubmed">19561505</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harel Z, Sholzberg M, Shah PS, et al.  Comparisons between novel oral anticoagulants and vitamin K antagonists in patients with CKD. J Am Soc Nephrol. 2014;25:431–442. doi: 10.1681/ASN.2013040361.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1681/ASN.2013040361</ArticleId>
            <ArticleId IdType="pmc">PMC3935586</ArticleId>
            <ArticleId IdType="pubmed">24385595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schulman S, Kearon C, Kakkar AK, et al.  Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013;368:709–718. doi: 10.1056/NEJMoa1113697.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1113697</ArticleId>
            <ArticleId IdType="pubmed">23425163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schulman S, Kearon C, Kakkar AK, et al.  Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361:2342–2352. doi: 10.1056/NEJMoa0906598.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa0906598</ArticleId>
            <ArticleId IdType="pubmed">19966341</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Investigators E-P, Buller HR, Prins MH, et al.  Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366:1287–1297. doi: 10.1056/NEJMoa1113572.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1113572</ArticleId>
            <ArticleId IdType="pubmed">22449293</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Investigators E, Bauersachs R, Berkowitz SD, et al.  Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363:2499–2510. doi: 10.1056/NEJMoa1007903.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1007903</ArticleId>
            <ArticleId IdType="pubmed">21128814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hokusai VTEI, Buller HR, Decousus H, et al.  Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369:1406–1415. doi: 10.1056/NEJMoa1306638.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1306638</ArticleId>
            <ArticleId IdType="pubmed">23991658</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agnelli G, Buller HR, Cohen A, et al.  Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368:699–708. doi: 10.1056/NEJMoa1207541.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1207541</ArticleId>
            <ArticleId IdType="pubmed">23216615</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agnelli G, Buller HR, Cohen A, et al.  Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369:799–808. doi: 10.1056/NEJMoa1302507.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1302507</ArticleId>
            <ArticleId IdType="pubmed">23808982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kleinow ME, Garwood CL, Clemente JL, Whittaker P. Effect of chronic kidney disease on warfarin management in a pharmacist-managed anticoagulation clinic. J Manag Care Pharm. 2011;17:523–530.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21870893</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garcia DA, Baglin TP, Weitz JI, Samama MM, College American of Chest P  Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e24S–e43S. doi: 10.1378/chest.11-2291.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1378/chest.11-2291</ArticleId>
            <ArticleId IdType="pmc">PMC3278070</ArticleId>
            <ArticleId IdType="pubmed">22315264</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hijazi Z, Hohnloser SH, Oldgren J, et al.  Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (randomized evaluation of long-term anticoagulation therapy) trial analysis. Circulation. 2014;129:961–970. doi: 10.1161/CIRCULATIONAHA.113.003628.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.113.003628</ArticleId>
            <ArticleId IdType="pubmed">24323795</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23:1296–1310. doi: 10.1016/S0149-2918(01)80109-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0149-2918(01)80109-0</ArticleId>
            <ArticleId IdType="pubmed">11558866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dabigatran prescribing information (2014) http://www.drugs.com/pro/pradaxa.html. Accessed 6 July 2015</Citation>
        </Reference>
        <Reference>
          <Citation>Apixaban prescribing information (2014) http://www.drugs.com/pro/eliquis.html. Accessed 6 July 2015</Citation>
        </Reference>
        <Reference>
          <Citation>Warfarin prescribing information (2014) http://www.drugs.com/pro/coumadin.html. Accessed 6 July 2015</Citation>
        </Reference>
        <Reference>
          <Citation>Rivaroxaban prescribing information (2014) http://www.drugs.com/pro/xarelto.html. Accessed 6 July 2015</Citation>
        </Reference>
        <Reference>
          <Citation>Kimmel SE, Chen Z, Price M, et al.  The influence of patient adherence on anticoagulation control with warfarin: results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study. Arch Intern Med. 2007;167:229–235. doi: 10.1001/archinte.167.3.229.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archinte.167.3.229</ArticleId>
            <ArticleId IdType="pubmed">17296877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Witt DM, Delate T, Clark NP, et al.  Nonadherence with INR monitoring and anticoagulant complications. Thromb Res. 2013;132:e124–e130. doi: 10.1016/j.thromres.2013.06.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.thromres.2013.06.006</ArticleId>
            <ArticleId IdType="pubmed">23800635</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clark NP, Witt DM, Delate T, et al.  Thromboembolic consequences of subtherapeutic anticoagulation in patients stabilized on warfarin therapy: the low INR study. Pharmacotherapy. 2008;28:960–967. doi: 10.1592/phco.28.8.960.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1592/phco.28.8.960</ArticleId>
            <ArticleId IdType="pubmed">18657012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weitz JI, Eikelboom JW, Samama MM, American College of Chest P  New antithrombotic drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e120S–e151S. doi: 10.1378/chest.11-2294.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1378/chest.11-2294</ArticleId>
            <ArticleId IdType="pmc">PMC3278067</ArticleId>
            <ArticleId IdType="pubmed">22315258</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Majeed A, Hwang HG, Connolly SJ, et al.  Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation. 2013;128:2325–2332. doi: 10.1161/CIRCULATIONAHA.113.002332.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.113.002332</ArticleId>
            <ArticleId IdType="pubmed">24081972</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hellwig T, Gulseth M. Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation? Ann Pharmacother. 2013;47:1478–1487. doi: 10.1177/1060028013504741.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1060028013504741</ArticleId>
            <ArticleId IdType="pubmed">24259602</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson SG, Rogers K, Delate T, Witt DM. Outcomes associated with combined antiplatelet and anticoagulant therapy. Chest. 2008;133:948–954. doi: 10.1378/chest.07-2627.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1378/chest.07-2627</ArticleId>
            <ArticleId IdType="pubmed">18198244</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lefebvre P, Coleman CI, Bookhart BK, et al.  Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism. J Med Econ. 2014;17:52–64. doi: 10.3111/13696998.2013.858634.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3111/13696998.2013.858634</ArticleId>
            <ArticleId IdType="pubmed">24156243</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bates SM, Greer IA, Middeldorp S, et al.  VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e691S–e736S.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3278054</ArticleId>
            <ArticleId IdType="pubmed">22315276</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang L, He K, Maxwell B, et al.  Tissue distribution and elimination of [14C] apixaban in rats. Drug Metab Dispos. 2011;39:256–264. doi: 10.1124/dmd.110.036442.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1124/dmd.110.036442</ArticleId>
            <ArticleId IdType="pubmed">21071521</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bapat P, Kedar R, Lubetsky A, et al.  Transfer of dabigatran and dabigatran etexilate mesylate across the dually perfused human placenta. Obstet Gynecol. 2014;123:1256–1261. doi: 10.1097/AOG.0000000000000277.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/AOG.0000000000000277</ArticleId>
            <ArticleId IdType="pubmed">24807346</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clark NP, Delate T, Witt DM, Parker S, McDuffie R. A descriptive evaluation of unfractionated heparin use during pregnancy. J Thromb Thrombolysis. 2009;27:267–273. doi: 10.1007/s11239-008-0207-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11239-008-0207-0</ArticleId>
            <ArticleId IdType="pubmed">18327536</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Crowl A, Schullo-Feulner A, Moon JY. Warfarin monitoring in antiphospholipid syndrome and lupus anticoagulant. Ann Pharmacother. 2014;48:1479–1483. doi: 10.1177/1060028014546361.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1060028014546361</ArticleId>
            <ArticleId IdType="pubmed">25104566</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schaefer JK, McBane RD, Black DF, Williams LN, Moder KG, Wysokinski WE. Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients. Thromb Haemost. 2014;112:947–950. doi: 10.1160/TH14-03-0272.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1160/TH14-03-0272</ArticleId>
            <ArticleId IdType="pubmed">25118790</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Crowther MA, Ginsberg JS, Julian J, et al.  A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003;349:1133–1138. doi: 10.1056/NEJMoa035241.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa035241</ArticleId>
            <ArticleId IdType="pubmed">13679527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Borgman MP, Pendleton RC, McMillin GA, et al.  Prospective pilot trial of PerMIT versus standard anticoagulation service management of patients initiating oral anticoagulation. Thromb Haemost. 2012;108:561–569. doi: 10.1160/TH12-03-0159.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1160/TH12-03-0159</ArticleId>
            <ArticleId IdType="pmc">PMC3434319</ArticleId>
            <ArticleId IdType="pubmed">22836303</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stergiopoulos K, Brown DL. Genotype-guided vs clinical dosing of warfarin and its analogues: meta-analysis of randomized clinical trials. JAMA Intern Med. 2014;174:1330–1338. doi: 10.1001/jamainternmed.2014.2368.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamainternmed.2014.2368</ArticleId>
            <ArticleId IdType="pubmed">24935087</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pirmohamed M, Burnside G, Eriksson N, et al.  A randomized trial of genotype-guided dosing of warfarin. N Engl J Med. 2013;369:2294–2303. doi: 10.1056/NEJMoa1311386.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1311386</ArticleId>
            <ArticleId IdType="pubmed">24251363</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kimmel SE, French B, Kasner SE, et al.  A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med. 2013;369:2283–2293. doi: 10.1056/NEJMoa1310669.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1310669</ArticleId>
            <ArticleId IdType="pmc">PMC3942158</ArticleId>
            <ArticleId IdType="pubmed">24251361</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>You JH. Pharmacoeconomic evaluation of warfarin pharmacogenomics. Expert Opin Pharmacother. 2011;12:435–441. doi: 10.1517/14656566.2011.521153.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1517/14656566.2011.521153</ArticleId>
            <ArticleId IdType="pubmed">21231897</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cryder B, Felczak M, Janociak J, Dela Pena L, Allen S, Gutierrez P. Prevalent aetiologies of non-therapeutic warfarin anticoagulation in a network of pharmacist-managed anticoagulation clinics. J Clin Pharm Ther. 2011;36:64–70. doi: 10.1111/j.1365-2710.2009.01155.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2710.2009.01155.x</ArticleId>
            <ArticleId IdType="pubmed">21198721</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grzymala-Lubanski B, Sjalander S, Renlund H, Svensson PJ, Sjalander A. Computer aided warfarin dosing in the Swedish national quality registry AuriculA–Algorithmic suggestions are performing better than manually changed doses. Thromb Res. 2013;131:130–134. doi: 10.1016/j.thromres.2012.11.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.thromres.2012.11.016</ArticleId>
            <ArticleId IdType="pubmed">23232091</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nieuwlaat R, Hubers LM, Spyropoulos AC, et al.  Randomised comparison of a simple warfarin dosing algorithm versus a computerised anticoagulation management system for control of warfarin maintenance therapy. Thromb Haemost. 2012;108:1228–1235. doi: 10.1160/TH12-06-0433.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1160/TH12-06-0433</ArticleId>
            <ArticleId IdType="pubmed">23015161</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poller L, Keown M, Ibrahim S, et al.  An international multicenter randomized study of computer-assisted oral anticoagulant dosage vs. medical staff dosage. J Thromb Haemost. 2008;6:935–943. doi: 10.1111/j.1538-7836.2008.02959.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1538-7836.2008.02959.x</ArticleId>
            <ArticleId IdType="pubmed">18489430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garcia DA, Witt DM, Hylek E, et al.  Delivery of optimized anticoagulant therapy: consensus statement from the Anticoagulation Forum. Ann Pharmacother. 2008;42:979–988. doi: 10.1345/aph.1L098.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1345/aph.1L098</ArticleId>
            <ArticleId IdType="pubmed">18559954</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>American Society of Health-System Pharmacists  ASHP therapeutic position statement on the use of low-molecular-weight heparins for adult outpatient treatment of acute deep-vein thrombosis. Am J Health Syst Pharm. 2004;61:1950–1955.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15487886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saokaew S, Permsuwan U, Chaiyakunapruk N, Nathisuwan S, Sukonthasarn A. Effectiveness of pharmacist-participated warfarin therapy management: a systematic review and meta-analysis. J Thromb Haemost. 2010;8:2418–2427. doi: 10.1111/j.1538-7836.2010.04051.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1538-7836.2010.04051.x</ArticleId>
            <ArticleId IdType="pubmed">20831620</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maynard G, Humber D, Jenkins I. Multidisciplinary initiative to improve inpatient anticoagulation and management of venous thromboembolism. Am J Health Syst Pharm. 2014;71:305–310. doi: 10.2146/ajhp130108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2146/ajhp130108</ArticleId>
            <ArticleId IdType="pubmed">24481155</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Christensen TD, Larsen TB. Precision and accuracy of point-of-care testing coagulometers used for self-testing and self-management of oral anticoagulation therapy. J Thromb Haemost. 2012;10:251–260. doi: 10.1111/j.1538-7836.2011.04568.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1538-7836.2011.04568.x</ArticleId>
            <ArticleId IdType="pubmed">22118602</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heneghan C, Ward A, Perera R, et al.  Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet. 2012;379:322–334. doi: 10.1016/S0140-6736(11)61294-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(11)61294-4</ArticleId>
            <ArticleId IdType="pubmed">22137798</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DeSantis G, Hogan-Schlientz J, Liska G, et al.  STABLE results: warfarin home monitoring achieves excellent INR control. Am J Manag Care. 2014;20:202–209.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24884750</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bajolle F, Lasne D, Elie C, et al.  Home point-of-care international normalised ratio monitoring sustained by a non-selective educational program in children. Thromb Haemost. 2012;108:710–718. doi: 10.1160/TH12-05-306.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1160/TH12-05-306</ArticleId>
            <ArticleId IdType="pubmed">22955724</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gaw JR, Crowley S, Monagle P, Jones S, Newall F. The economic costs of routine INR monitoring in infants and children–examining point-of-care devices used within the home setting compared to traditional anticoagulation clinic monitoring. Thromb Res. 2013;132:26–31. doi: 10.1016/j.thromres.2013.04.028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.thromres.2013.04.028</ArticleId>
            <ArticleId IdType="pubmed">23746471</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jones S, Monagle P, Manias E, Bruce AA, Newall F. Quality of life assessment in children commencing home INR self-testing. Thromb Res. 2013;132:37–43. doi: 10.1016/j.thromres.2013.05.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.thromres.2013.05.011</ArticleId>
            <ArticleId IdType="pubmed">23726963</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jowett S, Bryan S, Murray E, et al.  Patient self-management of anticoagulation therapy: a trial-based cost-effectiveness analysis. Br J Haematol. 2006;134:632–639. doi: 10.1111/j.1365-2141.2006.06243.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2141.2006.06243.x</ArticleId>
            <ArticleId IdType="pubmed">16938120</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Witt DM. Approaches to optimal dosing of vitamin K antagonists. Semin Thromb Hemost. 2012;38:667–672. doi: 10.1055/s-0032-1324713.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1055/s-0032-1324713</ArticleId>
            <ArticleId IdType="pubmed">22893509</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Banet GA, Waterman AD, Milligan PE, Gatchel SK, Gage BF. Warfarin dose reduction vs watchful waiting for mild elevations in the international normalized ratio. Chest. 2003;123:499–503. doi: 10.1378/chest.123.2.499.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1378/chest.123.2.499</ArticleId>
            <ArticleId IdType="pubmed">12576372</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schulman S, Melinyshyn A, Ennis D, Rudd-Scott L. Single-dose adjustment versus no adjustment of warfarin in stably anticoagulated patients with an occasional international normalized ratio (INR) out of range. Thromb Res. 2009;125:393–397. doi: 10.1016/j.thromres.2009.07.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.thromres.2009.07.006</ArticleId>
            <ArticleId IdType="pubmed">19640572</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van Spall HG, Wallentin L, Yusuf S, et al.  Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: an analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. Circulation. 2012;126:2309–2316. doi: 10.1161/CIRCULATIONAHA.112.101808.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.112.101808</ArticleId>
            <ArticleId IdType="pubmed">23027801</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Douketis JD, Spyropoulos AC, Spencer FA, et al.  Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e326S–e350S. doi: 10.1378/chest.11-2298.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1378/chest.11-2298</ArticleId>
            <ArticleId IdType="pmc">PMC3278059</ArticleId>
            <ArticleId IdType="pubmed">22315266</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Siegal D, Yudin J, Kaatz S, Douketis JD, Lim W, Spyropoulos AC. Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation. 2012;126:1630–1639. doi: 10.1161/CIRCULATIONAHA.112.105221.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.112.105221</ArticleId>
            <ArticleId IdType="pubmed">22912386</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Douketis JD, Spyropoulos AC, Kaatz S, Becker RC, Caprini JA, Dunn AS, Garcia DA, Jacobson A, Jaffer AK, Kong DF, Schulman S, Turpie AG, Hasselblad V, Ortel TL, Investigators BRIDGE. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med. 2015;379(9):823–833. doi: 10.1056/NEJMoa1501035.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1501035</ArticleId>
            <ArticleId IdType="pmc">PMC4931686</ArticleId>
            <ArticleId IdType="pubmed">26095867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clark NP, Witt DM, Davies LE, et al.  Bleeding, recurrent venous thromboembolism, and mortality risks during warfarin interruption for invasive procedures. JAMA Intern Med. 2015;175:1163–1168. doi: 10.1001/jamainternmed.2015.1843.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamainternmed.2015.1843</ArticleId>
            <ArticleId IdType="pubmed">26010033</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Callahan S, Goldsberry A, Kim G, Yoo S. The management of antithrombotic medication in skin surgery. Dermatol Surg. 2012;38:1417–1426. doi: 10.1111/j.1524-4725.2012.02490.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1524-4725.2012.02490.x</ArticleId>
            <ArticleId IdType="pubmed">22734794</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Steinberg BA, Peterson ED, Kim S, et al.  Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation: findings from the outcomes registry for better informed treatment of atrial fibrillation (ORBIT-AF) Circulation. 2015;131:488–494. doi: 10.1161/CIRCULATIONAHA.114.011777.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.114.011777</ArticleId>
            <ArticleId IdType="pmc">PMC4315748</ArticleId>
            <ArticleId IdType="pubmed">25499873</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tafur AJ, Wysokinski WE, McBane RD, et al.  Cancer effect on periprocedural thromboembolism and bleeding in anticoagulated patients. Ann Oncol. 2012;23:1998–2005. doi: 10.1093/annonc/mds058.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mds058</ArticleId>
            <ArticleId IdType="pubmed">22473596</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Crowther MA, Ageno W, Garcia D, et al.  Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. Ann Intern Med. 2009;150:293–300. doi: 10.7326/0003-4819-150-5-200903030-00005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7326/0003-4819-150-5-200903030-00005</ArticleId>
            <ArticleId IdType="pubmed">19258557</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Crowther MA, Garcia D, Ageno W, et al.  Oral vitamin K effectively treats international normalised ratio (INR) values in excess of 10. Results of a prospective cohort study. Thromb Haemost. 2010;104:118–121. doi: 10.1160/TH09-12-0822.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1160/TH09-12-0822</ArticleId>
            <ArticleId IdType="pubmed">20458438</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Crowther MA, Douketis JD, Schnurr T, et al.  Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy. A randomized, controlled trial. Ann Intern Med. 2002;137:251–254. doi: 10.7326/0003-4819-137-4-200208200-00009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7326/0003-4819-137-4-200208200-00009</ArticleId>
            <ArticleId IdType="pubmed">12186515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Crowther MA, Warkentin TE. Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents. J Thromb Haemost. 2009;7(Suppl 1):107–110. doi: 10.1111/j.1538-7836.2009.03429.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1538-7836.2009.03429.x</ArticleId>
            <ArticleId IdType="pubmed">19630780</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Quinlan DJ, Eikelboom JW, Weitz JI. Four-factor prothrombin complex concentrate for urgent reversal of vitamin K antagonists in patients with major bleeding. Circulation. 2013;128:1179–1181.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23935012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sarode R, Milling TJ, Jr, Refaai MA, et al.  Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation. 2013;128:1234–1243.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6701181</ArticleId>
            <ArticleId IdType="pubmed">23935011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tran HA, Chunilal SD, Harper PL, et al.  An update of consensus guidelines for warfarin reversal. Med J Aust. 2013;198:198–199. doi: 10.5694/mja12.10614.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5694/mja12.10614</ArticleId>
            <ArticleId IdType="pubmed">23451962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thachil J. Recurrent venous thromboembolism while on anticoagulant therapy. Blood Rev. 2012;26:175–181. doi: 10.1016/j.blre.2012.04.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.blre.2012.04.002</ArticleId>
            <ArticleId IdType="pubmed">22560652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee AY, Levine MN, Baker RI, et al.  Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146–153. doi: 10.1056/NEJMoa025313.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa025313</ArticleId>
            <ArticleId IdType="pubmed">12853587</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holbrook AM, Pereira JA, Labiris R, et al.  Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005;165:1095–1106. doi: 10.1001/archinte.165.10.1095.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archinte.165.10.1095</ArticleId>
            <ArticleId IdType="pubmed">15911722</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koplan KE, Brush AD, Packer MS, Zhang F, Senese MD, Simon SR. “Stealth” alerts to improve warfarin monitoring when initiating interacting medications. J Gen Intern Med. 2012;27:1666–1673. doi: 10.1007/s11606-012-2137-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11606-012-2137-y</ArticleId>
            <ArticleId IdType="pmc">PMC3509299</ArticleId>
            <ArticleId IdType="pubmed">22847620</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clark NP, Delate T, Riggs CS, et al.  Warfarin interactions with antibiotics in the ambulatory care setting. JAMA Intern Med. 2014;174:409–416. doi: 10.1001/jamainternmed.2013.13957.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamainternmed.2013.13957</ArticleId>
            <ArticleId IdType="pubmed">24445404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schurgers LJ, Shearer MJ, Hamulyak K, Stocklin E, Vermeer C. Effect of vitamin K intake on the stability of oral anticoagulant treatment: dose-response relationships in healthy subjects. Blood. 2004;104:2682–2689. doi: 10.1182/blood-2004-04-1525.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2004-04-1525</ArticleId>
            <ArticleId IdType="pubmed">15231565</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sconce E, Avery P, Wynne H, Kamali F. Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin. Blood. 2007;109:2419–2423. doi: 10.1182/blood-2006-09-049262.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2006-09-049262</ArticleId>
            <ArticleId IdType="pubmed">17110451</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rombouts EK, Rosendaal FR, Van Der Meer FJM. Daily vitamin K supplementation improves anticoagulant stability. J Thromb Haemost. 2007;5:2043–2048. doi: 10.1111/j.1538-7836.2007.02715.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1538-7836.2007.02715.x</ArticleId>
            <ArticleId IdType="pubmed">17666020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Majeed H, Rodger M, Forgie M, et al.  Effect of 200 muG/day of vitamin K1 on the variability of anticoagulation control in patients on warfarin: a randomized controlled trial. Thromb Res. 2013;132:329–335. doi: 10.1016/j.thromres.2013.07.019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.thromres.2013.07.019</ArticleId>
            <ArticleId IdType="pubmed">23953594</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gebuis EPA, Rosendaal FR, van Meegen E, van der Meer FJM. Vitamin K1 supplementation to improve the stability of anticoagulation therapy with vitamin K antagonists: a dose-finding study. Haematologica. 2011;96:583–589. doi: 10.3324/haematol.2010.035162.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3324/haematol.2010.035162</ArticleId>
            <ArticleId IdType="pmc">PMC3069236</ArticleId>
            <ArticleId IdType="pubmed">21193422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lam J, Schulman S, Witt DM, Vandvik PO, Qayyum F, Holbrook AM. Anticoagulation control with daily low-dose vitamin k to reduce clinically adverse outcomes and international normalized ratio variability: a systematic review and meta-analysis. Pharmacotherapy. 2013;33:1184–1190. doi: 10.1002/phar.1302.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/phar.1302</ArticleId>
            <ArticleId IdType="pubmed">23744743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Edoxaban prescribing information (2015) http://www.drugs.com/mtm/edoxaban.html. Accessed 6 July 2015</Citation>
        </Reference>
        <Reference>
          <Citation>Rose AJ, Hylek EM, Berlowitz DR, Ash AS, Reisman JI, Ozonoff A. Prompt repeat testing after out-of-range INR values: a quality indicator for anticoagulation care. Circ Cardiovasc Qual Outcomes. 2011;4:276–282. doi: 10.1161/CIRCOUTCOMES.110.960096.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCOUTCOMES.110.960096</ArticleId>
            <ArticleId IdType="pubmed">21505156</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patel RJ, Witt DM, Saseen JJ, Tillman DJ, Wilkinson DS. Randomized, placebo-controlled trial of oral phytonadione for excessive anticoagulation. Pharmacotherapy. 2000;20:1159–1166. doi: 10.1592/phco.20.15.1159.34585.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1592/phco.20.15.1159.34585</ArticleId>
            <ArticleId IdType="pubmed">11034038</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schillig J, Kaatz S, Hudson M, Krol GD, Szandzik EG, Kalus JS. Clinical and safety impact of an inpatient pharmacist-directed anticoagulation service. J Hosp Med. 2011;6:322–328. doi: 10.1002/jhm.910.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jhm.910</ArticleId>
            <ArticleId IdType="pubmed">21834113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Field TS, Tjia J, Mazor KM, et al.  Randomized trial of a warfarin communication protocol for nursing homes: an SBAR-based approach. Am J Med. 2011;124(179):e1–e7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21295198</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Motycka C, Kesgen C, Smith SM, Alvarez E, Jones K. Potential benefits of warfarin monitoring by a clinical pharmacist in a long term care facility. J Thromb Thrombolysis. 2012;33:173–177. doi: 10.1007/s11239-011-0642-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11239-011-0642-1</ArticleId>
            <ArticleId IdType="pubmed">21964972</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moreland CJ, Kravitz RL, Paterniti DA, Li CS, Lin TC, White RH. Anticoagulation education: do patients understand potential medication-related emergencies? Jt Comm J Qual Patient Saf. 2013;39:22–31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23367649</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tillman DJ, Charland SL, Witt DM. Effectiveness and economic impact associated with a program for outpatient management of acute deep vein thrombosis in a group model health maintenance organization. Arch Intern Med. 2000;160:2926–2932. doi: 10.1001/archinte.160.19.2926.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archinte.160.19.2926</ArticleId>
            <ArticleId IdType="pubmed">11041899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Efird LM, Mishkin DS, Berlowitz DR, et al.  Stratifying the risks of oral anticoagulation in patients with liver disease. Circ Cardiovasc Qual Outcomes. 2014;7:461–467. doi: 10.1161/CIRCOUTCOMES.113.000817.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCOUTCOMES.113.000817</ArticleId>
            <ArticleId IdType="pubmed">24823958</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Werner KT, Sando S, Carey EJ, et al.  Portal vein thrombosis in patients with end stage liver disease awaiting liver transplantation: outcome of anticoagulation. Dig Dis Sci. 2013;58:1776–1780. doi: 10.1007/s10620-012-2548-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10620-012-2548-y</ArticleId>
            <ArticleId IdType="pubmed">23314858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009;119:3028–3035. doi: 10.1161/CIRCULATIONAHA.108.768986.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.108.768986</ArticleId>
            <ArticleId IdType="pubmed">19528344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Truong T, Armor BL. Successful management of anticoagulation therapy during international travel. Pharmacotherapy. 2012;32:e45–e49. doi: 10.1002/j.1875-9114.2012.01019.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/j.1875-9114.2012.01019.x</ArticleId>
            <ArticleId IdType="pubmed">22392460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schwartz M. Travel and oral anticoagulants. J Travel Med. 2009;16:369–370. doi: 10.1111/j.1708-8305.2009.00353_1.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1708-8305.2009.00353_1.x</ArticleId>
            <ArticleId IdType="pubmed">19796112</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aerospace Medical Association Medical Guidelines Task Force  Medical guidelines for airline travel, 2nd ed. Aviat Space Environ Med. 2003;74:A1–A19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12817610</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kovacs MJ, Rodger M, Anderson DR, et al.  Comparison of 10 mg and 5 mg warfarin initiation nomograms together with low molecular weight heparin for outpatient treatment of acute venous thromboembolism. Ann Intern Med. 2003;138:714–719. doi: 10.7326/0003-4819-138-9-200305060-00007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7326/0003-4819-138-9-200305060-00007</ArticleId>
            <ArticleId IdType="pubmed">12729425</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schulman S, Hwang HG, Eikelboom JW, Kearon C, Pai M, Delaney J. Loading dose vs. maintenance dose of warfarin for reinitiation after invasive procedures: a randomized trial. J Thromb Haemost. 2014;12:1254–1259. doi: 10.1111/jth.12613.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jth.12613</ArticleId>
            <ArticleId IdType="pubmed">24837794</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baron TH, Kamath PS, McBane RD. Management of antithrombotic therapy in patients undergoing invasive procedures. N Engl J Med. 2013;368:2113–2124. doi: 10.1056/NEJMra1206531.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMra1206531</ArticleId>
            <ArticleId IdType="pubmed">23718166</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
